Evidence map›Paper›PMID 29086766›Full record

ArticleMolecular psychiatry2018

Secreted αKlotho isoform protects against age-dependent memory deficits.

A Massó, A Sánchez, A Bosch, L Giménez-Llort, M Chillón

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07216781 (Evaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07216781 phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans: An Interventional, Non-Placebo-Controlled Pilot Phase Study

TypeinterventionalSponsorMinicircleRan2025 to 2026Enrolled14ConditionsHealthy AdultsArmsInjectable Plasmid Klotho Gene Therapy
3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Klotho, PTSD, and advanced epigenetic age in cortical tissue.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A MassóDepartment of Biochemistry and Molecular Biology, Universitat Autònoma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.
A SánchezDepartment of Biochemistry and Molecular Biology, Universitat Autònoma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.
A BoschDepartment of Biochemistry and Molecular Biology, Universitat Autònoma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.
L Giménez-LlortInstitute de Neurociènces (INc), Universitat Autònoma Barcelona, Campus UAB, Bellaterra, Spain. lidia.gimenez@uab.cat.
M ChillónDepartment of Biochemistry and Molecular Biology, Universitat Autònoma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain. miguel.chillon@uab.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

αKlotho is a gene regulator of aging, increasing life expectancy when overexpressed and accelerating the development of aging phenotypes when inhibited. In mice, expression levels of the secreted isoform Klotho (s-KL) are very high in the brain, suggesting that s-KL activity may have an important role in the nervous system. Here we study the functional relevance at behavioural level of modifying s-KL levels in the aging brain. We used AAVrh10 vectors to deliver and sustained expression of s-KL in 6- and 12-month-old wild-type C57BL/6J males. This study demonstrates for we believe the first time in vivo that 6 months after a single injection of s-KL into the central nervous system, long-lasting and quantifiable enhancement of learning and memory capabilities are found. More importantly, cognitive improvement is also observable in 18-month-old mice treated once, at 12 months of age. These findings demonstrate the therapeutic potential of s-KL as a treatment for cognitive decline associated with aging.

Indexed as

Age FactorsAgingAnimalsBrainCognitive DysfunctionDisease Models, AnimalGene Expression RegulationGlucuronidaseKlotho ProteinsLearningMaleMemory DisordersMiceMice, Inbred C57BLProtein IsoformsSignal TransductionGlucuronidaseKlotho ProteinsProtein Isoforms

Identifiers

PMID29086766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.